3529 Brimonidine Brimonidine is only found in individuals that have used or taken this drug. It is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. [Wikipedia] A topical gel formulation, marketed under the name Mirvaso, was FDA approved on August 2013 for the treatment of rosacea. Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. 59803-98-4 2435 C11H10BrN5 291.011960 White powder. 207.5°C Soluble (1.5 mg/mL) Minimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment. Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction. Metabolized primarily by the liver. Route of Elimination: Urinary excretion is the major route of elimination of the drug and its metabolites. Half Life: 2 hours [ophthalmic solution] LD50: 50 mg/kg (oral, mice) LD50: 100 mg/kg (oral, rat) No indication of carcinogenicity to humans (not listed by IARC). The ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older. Oral LD₅₀ is 50 mg/kg in mice and 100 mg/kg in rats. 2009-07-30T17:58:43Z 2014-12-24T20:26:07Z Brimonidine C07886 3175 Brimonidine DB00484 true BrC1=C(NC2=NCCN2)C=CC2=C1N=CC=N2 C11H10BrN5 InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17) InChIKey=XYLJNLCSTIOKRM-UHFFFAOYSA-N 292.135 291.011957992 Exogenous Solid 1.7 HMDB14627 CHEMBL844 2341